The purpose of this study is to determine dexmedetomidine pharmacokinetics during continuous renal replacement therapy on critically ill patients.
Dexmedetomidine is a selective alpha-2-adrenergic agonist with sedative properties indicated for sedation of patients in the intensive care setting. ICU patients with acute kidney injury requiring renal replacement therapies frequently have changes in volume status causing alterations in drug pharmacokinetics. Although dexmedetomidine pharmacokinetics have been studied earlier on ICU patients, there is no information on its pharmacokinetics in critically ill patients needing continuous renal replacement therapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
Meilahti Hospital, Division of Anaesthesia and Intensive Care Medicine, Department of Surgery, Helsinki University Central Hospital
Helsinki, Finland
RECRUITINGDexmedetomidine clearance by continuous venovenous hemodialysis
Time frame: 10 hours from the start of the dexmedetomidine infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.